New Weight Loss Drug Shows Promise Without Nausea

Researchers at the University of Copenhagen have developed a drug that reduces appetite and increases calorie burning, potentially offering a side-effect-free alternative to current treatments.

The drug targets the Neurokinin 2 Receptor (NK2R), which is linked to energy balance and glucose control.
In studies, NK2R activation in mice and primates reduced body weight and improved insulin sensitivity without nausea.
The drug could benefit millions with obesity and type 2 diabetes who struggle with current GLP-1-based treatments.
Current GLP-1 drugs like Ozempic often cause side effects such as nausea, leading to high discontinuation rates.
Clinical trials for the new drug are expected to start within a year, with public availability projected in five to six years.